The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Biogen Inc (NASDAQ: BIIB) was $136.36 for the day, down -0.26% from the previous closing price of $136.72. In other words, the price has decreased by -$0.26 from its previous closing price. On the day, 1.4 million shares were traded. BIIB stock price reached its highest trading level at $138.5 during the session, while it also had its lowest trading level at $135.79.
Ratios:
Our analysis of BIIB’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.25 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.10. For the most recent quarter (mrq), Quick Ratio is recorded 1.79 and its Current Ratio is at 2.50. In the meantime, Its Debt-to-Equity ratio is 0.37 whereas as Long-Term Debt/Eq ratio is at 0.37.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jul 08 ’25 when Izzar Rachid sold 2,223 shares for $135.00 per share. The transaction valued at 300,105 led to the insider holds 6,330 shares of the business.
Izzar Rachid bought 2,223 shares of BIIB for $300,105 on Jul 08 ’25. On May 19 ’25, another insider, Singhal Priya, who serves as the Head of Development of the company, sold 3,806 shares for $126.25 each. As a result, the insider received 480,508 and left with 5,427 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BIIB now has a Market Capitalization of 19992422400 and an Enterprise Value of 23828166656. As of this moment, Biogen’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.05, and their Forward P/E ratio for the next fiscal year is 8.62. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.08 while its Price-to-Book (P/B) ratio in mrq is 1.13. Its current Enterprise Value per Revenue stands at 2.384 whereas that against EBITDA is 7.395.
Stock Price History:
The Beta on a monthly basis for BIIB is 0.12, which has changed by -0.33424473 over the last 52 weeks, in comparison to a change of 0.1590569 over the same period for the S&P500. Over the past 52 weeks, BIIB has reached a high of $206.70, while it has fallen to a 52-week low of $110.04. The 50-Day Moving Average of the stock is 4.05%, while the 200-Day Moving Average is calculated to be -0.98%.
Shares Statistics:
BIIB traded an average of 1.42M shares per day over the past three months and 1347940 shares per day over the past ten days. A total of 146.60M shares are outstanding, with a floating share count of 146.34M. Insiders hold about 0.19% of the company’s shares, while institutions hold 89.77% stake in the company. Shares short for BIIB as of 1755216000 were 4155186 with a Short Ratio of 2.92, compared to 1752537600 on 3896146. Therefore, it implies a Short% of Shares Outstanding of 4155186 and a Short% of Float of 3.66.
Earnings Estimates
The stock of Biogen Inc (BIIB) is currently drawing attention from 24.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is $3.46, with high estimates of $4.32 and low estimates of $2.81.
Analysts are recommending an EPS of between $16.18 and $13.92 for the fiscal current year, implying an average EPS of $15.72. EPS for the following year is $15.81, with 32.0 analysts recommending between $17.81 and $13.98.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 24 analysts. It ranges from a high estimate of $2.45B to a low estimate of $2.26B. As of the current estimate, Biogen Inc’s year-ago sales were $2.47BFor the next quarter, 24 analysts are estimating revenue of $2.26B. There is a high estimate of $2.44B for the next quarter, whereas the lowest estimate is $2.14B.
A total of 33 analysts have provided revenue estimates for BIIB’s current fiscal year. The highest revenue estimate was $10.03B, while the lowest revenue estimate was $9.09B, resulting in an average revenue estimate of $9.62B. In the same quarter a year ago, actual revenue was $9.68BBased on 33 analysts’ estimates, the company’s revenue will be $9.27B in the next fiscal year. The high estimate is $9.74B and the low estimate is $8.46B.
